Connect Biopharma Holdings Limited (NASDAQ:CNTB) announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16. The study met primary and secondary endpoints with mostly mild-to-moderate adverse effects reported. The data were presented as a late-breaking oral presentation today at the American Academy of Dermatology Annual Meeting, taking place in New Orleans, March 17-21.
Cryptocurrency Market Mutes As Focus Turns Back To GameStop, AMC Short Squeeze
The cryptocurrency market remained muted late Thursday as the focus returned to so-called meme stocks and associated short squeezes.
What Happened: Bitcoin (BTC), the largest cryptocurrency by market capitalization, traded 1.28% higher at $37,961.27 at press time over a 24-hour period. The apex coin is down 6.92% in a seven-day trailing period.
